Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy.
Physiol Res
November 2024
Children's Heart Centre, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Chronic heart failure (CHF) is a rare entity in children but carries a burden of high mortality and morbidity. Medical treatment of pediatric CHF is largely based on guidelines for the adult population. In contrast to adults, evidence for the efficacy of medications in treating CHF in children is sparse.
View Article and Find Full Text PDFDigoxin and its Na/K-ATPase-targeted actions on cardiovascular diseases and cancer.
Bioorg Med Chem
November 2024
Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States. Electronic address:
Na/K-ATPase (NKA) is a plasma membrane ion-transporting protein involved in the generation and maintenance of Na and K gradients across the cell membrane, which can produce a driving force for the secondary transport of metabolic substrates. NKA also regulates intracellular calcium that is responsible for modulating numerous cellular processes, while it interacts with many other proteins and functions as a signal transducer, with several signaling pathways being involved. Thus, NKA has become an important target for the treatment of human diseases.
View Article and Find Full Text PDFSafety and efficacy of up to 60 h of iv istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.
ESC Heart Fail
October 2024
Cardiovascular Markers in Stress Conditions (MASCOT), Université Paris Cité, Inserm UMR-S 942, Paris, France.
Article Synopsis
- Cardiogenic shock (CS) poses significant health risks, necessitating effective interventions to maintain blood pressure and tissue perfusion, while current treatments, like inotropes, can lead to serious side effects.
- The SEISMiC study aims to evaluate the safety and effectiveness of istaroxime, a new drug that may improve blood flow without overstimulating adrenergic receptors, in patients at risk for CS.
- This multinational, double-blind study involves patients with severe heart failure and aims to measure the drug's impact on blood pressure and other cardiac metrics over a 60-hour period, aiming to clarify istaroxime's potential benefits in managing pre-CS conditions.
A Comprehensive Review on Unveiling the Journey of Digoxin: Past, Present, and Future Perspectives.
Cureus
March 2024
Pediatrics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Digoxin, a cardiac glycoside derived from the foxglove plant ( spp.), has been utilized for centuries in managing various cardiac conditions due to its ability to increase myocardial contractility and regulate heart rate. This comprehensive review explores the historical context, pharmacological properties, clinical applications, efficacy, safety profile, challenges, and future perspectives of digoxin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!